November 2025
1. HERRINGTON WG, Judge PK, Grams ME, Wanner C, et al
   Chronic kidney disease.
   Lancet. 2025 Nov 25:S0140-6736(25)01942-7. doi: 10.1016/S0140-6736(25)01942.
   

   >> Share

   
   
2. THE LANCET
   Chronic kidney disease: breaking the silence.
   Lancet. 2025;406:2393.
   

   >> Share

   
   
3. HEERSPINK HJL, Cardona JF, Jolly S, Pergola PE, et al
   Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.
   Lancet. 2025 Nov 8:S0140-6736(25)02014-8. doi: 10.1016/S0140-6736(25)02014.
   

   >> Share

   
   
4. JHA V
   Augmenting nephroprotection: balcinrenone plus dapagliflozin in chronic kidney disease.
   Lancet. 2025 Nov 8:S0140-6736(25)02126-9. doi: 10.1016/S0140-6736(25)02126.
   

   >> Share

   
   
5. 
   Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023.
   Lancet. 2025 Nov 7:S0140-6736(25)01853-7. doi: 10.1016/S0140-6736(25)01853.
   

   >> Share

   
   August 2025
6. PYNE L, Rossignol P, Giles C, Junek M, et al
   Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials.
   Lancet. 2025;406:811-820.
   

   >> Share

   
   
7. SOOMRO QH, Charytan DM
   Requiem for mineralocorticoid blockade in maintenance dialysis.
   Lancet. 2025;406:780-782.
   

   >> Share

   
   
8. ROSSIGNOL P, Zannad F, Massy Z, Azizi M, et al
   Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.
   Lancet. 2025;406:705-718.
   

   >> Share

   
   
9. WALSH M, Collister D, Gallagher M, Mark PB, et al
   Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial.
   Lancet. 2025;406:695-704.
   

   >> Share

   
   May 2025
10. LOU-MEDA R, Perez JB
    Reducing the burden of chronic kidney disease in the world.
    Lancet. 2025 May 9:S0140-6736(25)00548-3. doi: 10.1016/S0140-6736(25)00548.
    

    >> Share

    
    October 2024
11. RANCHIN B, Shroff R
    Haemodiafiltration improves survival in patients receiving dialysis.
    Lancet. 2024 Oct 25:S0140-6736(24)01938-X. doi: 10.1016/S0140-6736(24)01938.
    

    >> Share

    
    August 2024
12. MARECEK R, Kissling S, Teso AD, Vuignier Y, et al
    Chronic metabolic acidosis in a patient with diabetes on maintenance haemodialysis: mind the anion gap.
    Lancet. 2024;404:570-571.
    

    >> Share

    
    March 2024
13. WONG K, Pitcher D, Braddon F, Downward L, et al
    Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort.
    Lancet. 2024;403:1279-1289.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share